The week in industry: BenevolentAI secures $90 million investment to advance their drug development programs
This week: NHS England determines Vertex’s drug cost not justified, Multiple myeloma antibody treatment given FDA Orphan Drug Designation and Acceleron (MA, USA) discontinues development of muscular dystrophy drug.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>